662
Participants
Start Date
March 29, 2011
Primary Completion Date
January 3, 2012
Study Completion Date
January 3, 2012
CD2475/101 40 mg
Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
Doxycycline 100 mg
Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
Placebo
Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Helendale Dermatology & Medical Spa, Rochester
Stephen Schleicher, Hazleton
Dermatology Consulting Services, High Point
PMG Research of Wilmington, Wilmington
Palmetto Clinical Trial Services, LLC, Greenville
MedaPhase, Inc., Newnan
International Dermatology Research, Inc., Miami
Dermatology Research Associates, Nashville
Tennessee Clinical Research Center, Nashville
Dermatology Specialists PC, Louisville
Haber Dermatology & cosmetic Surgery, Inc, South Euclid
Somerset Skin Care Center, Troy
Grekin Skin Care, Warren
Central Dermatology, PC, St Louis
Skin Specialists, PC, Omaha
Burke Pharmaceutical Research, Hot Springs
Central Sooner Research, Norman
Arlington Center for Dermatology, Arlington
Suzanne Bruce and associates P.A. The Center for skin Research, Houston
Center for Clinical Studies, Houston
J&S Studies, College Station
Progressive Clinical Research, San Antonio
Stephen Miller MD, San Antonio
Derm Research, Inc, Austin
Colorado Medical Research Center, Denver
Longmont Medical Research Network, Longmont
Dermatology Research Center, Salt Lake City
Academic Dermatology, Albuquerque
Dermatology Research Associates, Inc., Los Angeles
Oregon Dermatology & Research Center, Portland
Premier Clinical Research, Spokane
Lead Sponsor
Galderma R&D
INDUSTRY